TRANSTHERA-B (02617) announced its annual results for the period ending December 31, 2025. Other income and gains fell by 48.6% year-on-year to 9.2 million yuan (Renminbi) for the 2025 fiscal year. This decrease was primarily attributed to a reduction of 5 million yuan in bank deposit interest and wealth management income, alongside a 3.7 million yuan decrease in government grants compared to the same period last year. The company reported a net loss of 296 million yuan, representing a 7.8% widening compared to the previous year. The basic loss per share was 0.76 yuan. Research and development costs saw a modest increase of 1% year-on-year to 246.8 million yuan for 2025, remaining relatively stable with a slight uptick. This reflects the company's continued focus on developing core products and key technologies, optimizing resource allocation, and persistently enhancing product competitiveness. All product pipelines are currently progressing smoothly, with milestones being achieved as anticipated. During the reporting period, TT-00420 (Tienigotinib) was approved by China's Center for Drug Evaluation (CDE) for inclusion in the "Priority Review List." The company has submitted a New Drug Application (NDA), which has been accepted, positioning the product to enter the commercialization phase initially in China. Furthermore, the international multi-center Phase III clinical trial for the cholangiocarcinoma program is advancing steadily.